Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Medtech Nears its Golden Age Focusing on Value-based Care


Asia-Pacific to overtake Europe as the second largest market by 2022, finds Frost & Sullivan

SANTA CLARA, Calif., June 24, 2019 /CNW/ -- The key medtech industry challenges of lack of innovation in conventional segments, the evolution of GAFAM (Google, Amazon, Facebook, Apple, and Microsoft) and other non-traditional participants, has led to certain industry moves broadly classified into increasing personalization, data and tech leverage, enhanced post-acute care coordination and an increasing focus on value-based care models. Furthermore, Asia-Pacific, driven by the rising adoption of emerging technologies in countries like Japan, China, Singapore, and India, is creating a key growth region. It and is set to account for one-fourth of the global market by 2019 and overtake Europe as the second-largest market by 2022.

Medical Technology

"Patient centricity is a major theme for the medtech industry, with focus continuing to develop around key areas of patient safety, monitoring, engagement, and care coordination - but this time empowered with digital tools, and focusing on newer areas of growth," said Sowmya Rajagopalan, Advanced Medical Technologies Global Director. "Patient safety, for instance, which traditionally involves areas such as surgical site infections, is now expanding the scope to cover diagnostics safety, pressure ulcers and preventing unnecessary emergency department admissions. These newer focus areas are expected to grow at a 14.7% CAGR until 2024."

Frost & Sullivan's recent analysis, Global Medical Technologies Industry Predictions, 2019, comprehensively analyzes a set of 20 such growth opportunities cutting across these themes, with a combined incremental value of $64.10 billion, over and above the $413.90 billion traditional market size, in 2019. The estimates further peg the longer-term growth opportunity to be $173.06 billion by 2024, with a healthy CAGR of 22.0% compared to the traditional market, which is estimated to slow down from the current 5.8% to around 5.2% by 2024.

For further information on this analysis, please visit: http://frost.ly/3ie.

"The medtech industry has been challenged by the lack of innovation in conventional segments, increasing focus on efficiencies, changing device ecosystem to digital enablers, and rising domestic competition in certain growth markets," noted Rajagopalan. "This has resulted in a series of industry strategies broadly classified into increasing personalization, data and tech leverage, enhanced post-acute care coordination, and a focus on value-based care models."

Top medtech companies are adopting the following strategies to tap growth opportunities:

Global Medical Technologies Industry Predictions, 2019 is part of Frost & Sullivan's global Advanced Medical Technologies Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Global Medical Technologies Industry Predictions, 2019
K2D7-54

Contact:
Mariana Fernandez
T: +1 210 348 10 12
T: +54 11 4778 3540
E: [email protected]

http://ww2.frost.com

SOURCE Frost & Sullivan


These press releases may also interest you

at 22:33
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

at 22:03
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

at 19:30
Astellas Pharma Inc....

at 19:15
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...



News published on and distributed by: